Technology

Our liver-targeting RiboGalSTAR^TM delivery technology enables siRNA delivery to various hepatic targets for relevant indications.

Our RiboGalSTAR^TM platform has advanced seven programs into clinical development. Its high potency, prolonged duration, and favorable safety profile are clinically validated. This marks it as one of the most productive GalNAc platforms globally, with patents secured in major jurisdictions, including China, Europe, and the United States.

We are developing RiboOncoSTAR^TM, a leading tumor-targeted platform leveraging oligonucleotide-conjugate delivery technology, to support our development of multiple potentially first-in-class cancer treatments.

In preclinical studies, RiboOncoSTAR^TM has demonstrated superior anti-tumor effects and safety profiles in selected cancer (including glioma, pancreatic cancer) versus standard-of-care treatments.

RiboPepSTAR^TM is Ribo’s delivery technology achieves extrahepatic organ targeting via molecular conjugation.

The platform shows efficacy exceeding existing therapies in preclinical models for renal and CNS delivery. Combined with its favorable safety profile, this positions us at siRNA innovation's global forefront.

RiboColorSTAR^TM is our proprietary siRNA delivery platform designed for extrahepatic tissues.

By optimized lipophilic ligand structures and delivery-related properties, the platform modulates siRNA biodistribution, cellular uptake, and tissue selectivity, enabling efficient enrichment and functional delivery in selected extrahepatic tissues.

RiboColorSTAR^TM supports siRNA development for diseases involving adipose, skeletal muscle, the central nervous system (CNS), and other extrahepatic organs, expanding RNA therapeutics beyond conventional liver-targeted delivery.

Our proprietary RSC (Ribo Stabilization Chemistry) platform is a proprietary iterative siRNA chemical modification technology platform based on systematic studies of siRNA degradation mechanism, sequence activity, off-target rules and durability.

The synergy between RSC and our RiboGalSTAR^TM delivery technology is demonstrated by the favorable safety profile and sustained efficacy of RBD4059 and other clinical-stage assets.

RiboGalPLEX^TM is our liver-targeted, multi-target siRNA platform designed to modulate two or more liver disease-related targets with a single therapeutic molecule.

Based on GalNAc-mediated liver delivery and modular molecular design, the platform enables flexible assembly of different siRNA functional units and tunable silencing ratios among targets.

RiboGalPLE^TM is well suited for liver diseases driven by multiple pathogenic pathways, offering a streamlined and efficient strategy for multi-target intervention.

RiboCygnus^TM is our proprietary next-generation siRNA platform for extrahepatic dual-target intervention, which enables simultaneous silencing of two disease targets while remaining compatible with extrahepatic delivery technologies. 

RiboCygnus^TM provides a differentiated siRNA development strategy for CNS and other extrahepatic diseases with complex pathogenesis.

Leveraging on our in-house capacity for modeling and simulation techniques, we perform quantitative analysis of drug-disease data to gain mechanistic insights into siRNA action and enhance predictive accuracy throughout drug development stages. 

We have developed our own proprietary software for the design of siRNA sequences.
This platform enables rapid identification of high-quality siRNA candidates by analyzing key parameters such as off-target gene prediction, cross-species comparison, and sequence homology. It ensures optimal specificity and activity in selected sequences.
Complementing this, our high-throughput screening platform efficiently generates and evaluates lead oligonucleotide compounds, accelerating the discovery and optimization process.